Merz Therapeutics, Raleigh, NC 27615, USA.
Aetion, New York, NY 10001, USA.
Toxins (Basel). 2024 Aug 17;16(8):366. doi: 10.3390/toxins16080366.
Chronic sialorrhea is a condition characterized by excessive drooling, often associated with neurological and neuromuscular disorders such as Parkinson's disease, cerebral palsy, and stroke. Despite its prevalence, it remains underdiagnosed and poorly understood, leading to a lack of comprehensive data on patient demographics, clinical characteristics, and treatment patterns. This study aimed to help fill these existing gaps by analyzing real-world data using Optum's de-identified Clinformatics Data Mart Database. Patients were required to have a diagnosis indicative of sialorrhea plus evidence of sialorrhea treatment between 1/1/2007 and 5/31/2022. Two cohorts were analyzed: patients with evidence of newly diagnosed sialorrhea and associated treatment, and sialorrhea patients initiating incobotulinumtoxinA. Clinical characteristics, comorbidities, symptoms, and treatment utilization were described before and after diagnosis and incobotulinumtoxinA initiation. No formal statistical comparisons were performed. Patients were predominantly aged 65 or older, male, and non-Hispanic white. Parkinson's disease and cerebral palsy were the most common comorbidities among adults and children, respectively. Treatment patterns suggest that anticholinergics are more commonly used than botulinum toxin therapy. The findings offer valuable information for improving diagnosis and treatment approaches and suggest a need for further research into treatment effectiveness, safety, and disease burden.
慢性唾液过多症是一种以过度流涎为特征的病症，常与帕金森病、脑瘫和中风等神经和神经肌肉疾病有关。尽管它很普遍，但仍未得到充分诊断和理解，导致缺乏关于患者人口统计学、临床特征和治疗模式的全面数据。本研究旨在通过使用 Optum 的去识别 Clinformatics Data Mart 数据库分析真实世界数据来帮助填补这些现有空白。患者必须在 2007 年 1 月 1 日至 2022 年 5 月 31 日期间有唾液过多的诊断证据和唾液过多治疗的证据。分析了两个队列：有新诊断的唾液过多和相关治疗证据的患者，以及开始使用 incobotulinumtoxinA 的唾液过多患者。在诊断和开始使用 incobotulinumtoxinA 前后描述了临床特征、合并症、症状和治疗利用情况。未进行正式的统计比较。患者主要年龄在 65 岁或以上，男性，非西班牙裔白人。帕金森病和脑瘫分别是成人和儿童中最常见的合并症。治疗模式表明，抗胆碱能药物的使用比肉毒毒素治疗更常见。这些发现为改善诊断和治疗方法提供了有价值的信息，并表明需要进一步研究治疗效果、安全性和疾病负担。
